

Cumulative Index 2004

Volume 27

March	COGNITIVE AND NEUROLOGIC IMPAIRMENTS IN PSYCHIATRIC DISORDERS, pages 1-186
June	ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER, pages 187-390
September	DISASTER PSYCHIATRY: A CLOSER LOOK, pages 391-610
December	ADDICTIVE DISORDERS, pages 611-852

Note: Page numbers of article titles are in **boldface** type.

A

- ABT-418, for ADHD, 380-381
- Acamprosate, for alcohol addiction, 635-636
- Acetylcholine, in basal ganglia circuitry, 780-781
- Adderall. See *Amphetamine (Adderall)*.
- Addiction, occupational exposure and, **743-751**. See also *Anesthesiologists, addiction in; Physicians, addiction in*.
of physicians and anesthesiologists, 744-749
as problem, 743-744
physicians and anesthesiologists at risk for, 744-745
- Addiction psychiatry, addiction treatment in jails and prisons and, 621-622
forensic and medical issues in, **611-626**
addiction treatment in jails and prisons, 621
child custody in, 617-618
civil matters in, 613-614
competencies in, civil, 614
to stand trial, 618
confidentiality in, 616-617
criminal matters in, 618-621
diminished capacity in, 619
disability and, 614-616
driving offenses, alcohol and drug-related, 620-621
duty to protect or warn in, 617-618
impairment and fitness to practice, 622-623
- involuntary commitment and, 613-614
liability and, 624
pregnancy in, harm to fetus and child abuse and, 619-620
professional liability in, 616
regulatory matters in, 622-624
sanity in, 618-619
tissue testing in, 623-624
forensic evaluation vs. clinical evaluation in, 612-613
diagnosis and language in, 613
forensic psychiatry in, description of, 611-612
- Addictive disorders. See also *Substance use disorders*.
medical comorbidity in, **675-686**
alcohol use and, 677-681
amphetamine use and, 682-683
cocaine use and, 681-682
opiate use and, 683-684
tobacco use and, 675-677
and psychiatric disorders. See also *Drug withdrawal*.
neurobiological mechanisms in, **661-674**
relapse prevention in, **627-648**
- Adolescents, trauma and, reaction to, 494-495
- Adrenergic blocking agents, for cocaine addiction, 641-642
- Adult Self-Report Scale (ASRS), for ADHD, 198-199

- Affective disorders, co-occurring substance use disorders and, **649-659**
differentiation from substance-induced states, 650-651
- Agitation, psychomotor, in mood disorders, 28
- Alcohol dependence, pharmacotherapies for, 628-629
- Alcoholism. See *Alcohol use/abuse*.
- Alcohol use/abuse. See also *Substance use disorder (SUD)*.
in adults with ADHD, impact on driving, 243-246
cardiomyopathy and, 679-680
cirrhosis and, mortality from, 681
cognitive-behavioral therapy for, 711
cognitive impairment from, long-term, 99-100
in recent detoxification, 99
coronary heart disease and, 680
diabetes and, 678
hypertension and, 678-679
neurophysiological changes with, 99
in Parkinson's disease, 803
pathological, post-disaster, 444-445
pharmacotherapies for, acamprosate, 635-636
disulfiram, 633-634
naltrexone, 634-635
serotonergic agents, 635
topiramate, 636
prescription opiates in, contraindication to, 687
risks and benefits of, 677-678
stroke and, 680
- Alcohol withdrawal, anxiety and depression in, 665
corticotropin-releasing factor systems in, 665
- Alpha₂-receptor agonists, in disaster therapy, 437
post-disaster, 437
- Alpha₁-receptor antagonists, post-disaster, 437
- Alzheimer's disease, mood disorders and, 22
- Amantadine, for cocaine addiction, 640
- Amphetamine abuse, cognitive impairment from, 102-103
- Amphetamine (Adderall), for ADHD, in adults, 369-371
Massachusetts General Hospital study of, 369-370
- Amphetamine extended-release (Adderall-XR), for ADHD, in adults, multi-site trial of, 370-371
- Amphetamine use, cardiovascular effects of, 682-683
neurotoxicity with HIV medications
- Amphetamine withdrawal, anhedonia in, 664-665
deficit in brain reward function in, 664-665
- Amygdala, anatomy of, 57-58
in conditioned fear, startle, physiological reactivity, 57-58
in conditioned fear response, 58-59
partial kindling in, in conditioned fear, startle, physiological reactivity, 58
in stress reactions, 426-427
- Anesthesia, recreational use of, 745
- Anesthesiologists, addiction in, case histories of, 745-747
opiate addiction in, neurobiology of exposure and, 747-749
- Anger, hostility, and aggression (road rage), in ADHD, in adolescents, 251
in adults, 250-251
independent of ADHD, 251-252
studies of, 250
- Antalarmin, posttrauma, 440
- Anticonvulsants, for bipolar disorder, in children and adolescents, 160-163
combinations of, 164-165
novel, 163-164
in chronic PTSD, 443-444
for comorbid substance abuse and bipolar disorder, 656
in disaster therapy, 443-444
- Antidepressants, for depressive illnesses, in children and adolescents, studies of, 120-121
myoclonus from, 29-30
- Antipsychotics, in acute stress disorder, 443
atypical, 7
in bipolar disorders, in children and adolescents, 165-167
in chronic PTSD, 442
comparison with lithium, in mania and schizoaffective mania, 165
conventional, 7
volume changes in subcortical and cortical regions and, 7-8
in disaster therapy, 442-443

- Antisocial disorders, in ADHD, substance use disorder and, 291
- Anxiety/anxiety disorders, disasters and, long-term aftermath of, 403
in face of ongoing threat, 403-404
in Parkinson's disease, 801-802
in progressive supranuclear palsy, 810
- Anxiety disorders, comorbid with substance use disorders, 667-668
- Assertive community treatment (ACT), for dual-diagnosis patients, 711-712
substance abuse and, 712
- Astressin, posttrauma, 440
- Atomoxetine, for ADHD, in adults, 378-380
in children and adolescents, 377-378
for driving performance, 255
with substance use disorder, 294
- Attentional bias, in posttraumatic stress disorder, 61
- Attention deficit hyperactivity disorder (ADHD), in adults, 303-304
brain function and structure in, 323-347
and in children of, 313
comorbidity in, 190
coping skills and, 195
cultural considerations and, 194
current symptom surveys for, 197-199
diagnosis and evaluation of, 187-201
diagnosis of, 190-195
diagnostic scales for, 196-197
educational outcomes in, 193
gender and, 194
neurological function in, 261-282
nonstimulant treatment of, 373-383
occupational challenges and, 192-193
presenting problems in, 191-192
prevalence of, 349
psychosocial treatments for, 349-360
relationships and family life and, 193-194
stimulant treatment of, 361-372
symptom criteria for, 189-190
treatment of, behavioral and cognitive therapies for, 292
nonstimulants in, 373-383
psychosocial, 349-360
stimulants in, 361-372
age and, 215-224
animal models of, colomaba mouse, 311-312
monkey, 307
methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in, 307
rat model of hyperactivity, methylenedioxy-methamphetamine in, 312-313
spontaneously hypertensive rat, 307-308
attention-executive dysfunction
concept in, 262-263
brain function and structure in, 323-347
characterization of, 83, 303-304
cognition in, 84-86
comorbidity in, driving impairments and, studies of, 235-236
familial transmission of, gender and, 228, 230-231
genetics and, 304
substance use disorders and, 284-285, 293-295
diagnosis of, 190-195, 324
current, 324
scales for, 196-197
diagnostic construct of, 262
drivers with, driving performance models and, 236-238
risks in, 238-242
driving impairments in, 233-260
anger, hostility, aggression and, 250-252
risks for, 233-235
large-scale study of, 240-242
pilot study of, 238-240
self-evaluation of performance and, 246-249
substance use disorder effect on, 227-230, 243-246
in DSM-II, 188, 208
in DSM-III, 188, 210
in DSM-III-R, 188-189, 210-211
in DSM-IV, 189, 211-212
in DSM-IV-TR, 189-190, 212
environmental factors in, 305-306, 315
executive dysfunction in, 83-96
cognitive remediation for, 91-92
examples and descriptions of, 84-85
neural substrates of, 91
psychostimulant medication in, 91
stimulant medications research and, 85-86

Attention (*continued*)

executive function/dysfunction in,
functional neuroimaging studies
of, 86-88
gender effect on, 269-270
and response inhibition, brain
mapping of, 273-274

executive functions in, frontal-striatal-
thalamic-cortical circuitry in, 86
functional neuroimaging studies
of, 86-88

neuroanatomy of, 86-88

familial transmission of, 313-315

psychiatric comorbidity in,

gender and, 228, 230-231

reporter bias issue in, 314-315

functioning in, heterogeneity of, in
persistent and remitted cases,
220-222

gender influence on, **225-232**

in clinical presentation, 227-228,
231

Massachusetts General Hospital

studies of, 225-232

methods in, 226-227

psychiatric comorbidity

and, 227, 229

psychiatric disorders among

parents and siblings,

228-230

substance use disorders and,

227-230

subtypes in, 227-228

genetics of, **303-321**

heterogeneity of, and brain

abnormalities, 334

history of, in adults, 187-188,

203-214

terminology in, 207-210,

262, 324

attention-deficit vs. hyperactivity
in, 210

Benzedrine for, 206

biologic etiology in, 205

brain damage and, 205-206

hyperkinetic reaction of

childhood, 208-209

minimal brain damage label in,
206-208

moral control notion in, 204

persistence into adulthood,

209-210

1930s, 205-206

19th century, 203-204

World War I, 205

hyperactive/impulsive type, 227-228,
230

inattentive type, 227-228, 230

Massachusetts General Hospital

studies of, **225-232**, 378-381

molecular studies of, catechol-o-

methyltransferase gene in, 311

dopamine receptor genes,

308-309, 311

dopamine system genes in,

307-311

dopamine transporter gene,

310-311

serotonergic system in, 312-313

neuroimaging in, functional, 89-90

literature for, 90-91

neurochemical, 90

structural, 88

structure-executive function

correlation in, 88

neurological function in, **261-282**

nonstimulant treatment of, **373-383**

ABT-418 in, 380-381

cholinergic agents and,

380-381

desipramine in, 373-375

monoamine oxidase inhibitors in,

376

SSRIs in, 376-377

venlafaxine in, 377

persistent form of, genetics of,

313-315

syndromic in children and adults,

338

prevalence of, 83

psychosocial treatments for, **349-360**

remission in, syndromic vs.

symptomatic, 219-220

risks for, 304

stimulant treatment of, in children and

adolescents, 361-362

comorbidity and, 361-362

substance use disorder in, **283-301**. See

also *Substance use disorder*

(*SUD*), in *ADHD*.

impact on driving, 243-246

subtypes of, 227-228, 324

symptoms in, 188-190

in adults with substance use

disorder, 291-292

decline in, age-dependent,

216-218

impact on persistence rates,

218-220

Attention-executive dysfunction, in

ADHD, 262-263, 267-268

development of, 324-325

gender effect on, 269-270

Attention/working memory, in mood

disorders, impaired, 22-23

- structural and functional abnormalities of brain regions in, 25
 - Atypical antipsychotics, 7
 - in schizophrenia, caudate enlargement and, secondary to conventional neuroleptic therapy, 8
 - Avoidant behavior, in children, posttraumatic, 475
 - in countertransference, 574-575
 - B**
 - Baclofen, for cocaine addiction, 641
 - Basal ganglia, **755-796**
 - anatomy of, fronto-striatal circuits, 760-768
 - pallidum, 758-759
 - striatum, 756-758
 - substantia nigra reticula, 759-760
 - subthalamic nucleus, 762
 - neuroimaging studies of, in ADHD in children, 329-330
 - in adults with ADHD, 337
 - pharmacology of, acetylcholine in, 780-781
 - dopamine in, 778-780
 - glytamate in, 781-782
 - serotonin in, 782
 - physiology of, 770-778
 - activity at rest, 771
 - motor networks in, 774-776
 - frequency-dependent activation of, 776-778
 - neuronal responses in, activity-related, 771-774
 - in psychiatric disorders, 755
 - role in cognition and emotion, 755
 - Behavioral interventions, in ADHD, for driving impairments and adversities, 253-254
 - Benzodiazepines, in disaster therapy, 437-439
 - in emergency trauma treatment, 561
 - posttrauma, 438-439
 - in PTSD, 437-438
 - prevention of, 438
 - Best practice. *See also Evidence-based best practice.*
 - in dual-diagnosis treatment, 728
 - Beta-adrenergic blockers, post-disaster, 435-437
 - Beta adrenergic blocking agents, in disaster therapy, 435-437
 - Bipolar disorder. *See also Depression.*
 - in ADHD, 192, 285
 - substance use disorder and, 290-291
 - in children and adolescents, anticonvulsants for, 160-163
 - combinations of, 164-165
 - novel, 163-164, 169
 - antipsychotics for, 165-167
 - calcium-channel blockers for, 168
 - carbamazepine for, 162-163
 - clozapine for, 165-166
 - electroconvulsive therapy for, 167
 - gabapentin for, 164
 - lamotrigine for, 163-164
 - olanzapine for, 166-167
 - omega-3 fatty acids for, 168
 - quetiapine for, 166
 - risperidone for, 166
 - somatic treatment of, **153-176**
 - duration of, 154
 - medication choice in, 154
 - valproate for, 160-161
 - cognitive deficits in, frontal lobe function and, 26
 - co-occurrence of substance use disorders in, 655-657
 - pharmacologic treatments for, 655-656
 - psychosocial treatments for, 656
 - executive function in, 23
 - symptom criteria for, DSM-IV, 21
- Borderline personality disorder (BPD), developmental studies of, contributions of psychosocial factors and neuropsychological factors, 68
 - executive functions and, 68
 - frontal lobe and executive functions in, 68
 - neuropsychological dysfunction and attention deficit disorder in, 68
- empirical study of inpatients, 71-75
 - agitation-excitement factor of, 75-76
 - areas of psychopathology and performance in, 75-76
 - correlations between psychopathology and neuropsychological functioning, 78
 - limitations of, 78-79
 - materials and procedure in, 73-74
 - neurological abnormalities in, 75-76
 - neuropsychological impairment in, across cognitive domains, 76

Borderline (continued)

- attention deficit, 77
- verbal learning and memory deficits, 77-78
- neuropsychological tests in, 72-73
- participants in, 73
- results of, 74-75
 - cognitive performance below normative group, 74-75
- tests per cognitive domain in, 72-73
- treatment implications of, cuing strategies, 80
- Dialectical Behavior Therapy in, 80
- psychoeducational strategies, 80
- screening for cognitive impairment, 79
- neuroimaging studies of, 69-70
 - frontal and hippocampal compromise on, 78
- neurological studies of, discussion of, 75-78
 - limitations of, 78-79
- neurophysiological profile of, limitations to research in, 67-68
- neuropsychological impairment in, 67-82
- neuropsychological studies of, 70
 - cognitive functioning deficits in, 70-71
 - consistent findings in, 71
 - previous studies of, CT, 69
 - electroencephalogram abnormalities in, 69
 - positron emission tomography, 69-70
 - prevalence of soft signs in, 69
 - studies of, empirical of inpatients, 70-75
 - findings in, 70-71
 - neuroimaging, 69-70
 - neurological, 69
 - review of previous, 69-71

Brain, in ADHD, structure and function of, 323-347

- affective abnormalities and, 339
- neuropsychological dysfunction and, 333
- relationships of, 338
- research needs in, 338-339
- in mood disorders, structural and functional abnormalities of, 24-27

Brain abnormalities, in ADHD, gender effect and, 334-336

- in ADHD in children, learning disabilities and, 332
 - mood disorders and, 332-333
 - psychiatric comorbidity and, 331-332
 - in heterogeneity of ADHD, 334
- Brain dysfunction, in ADHD, attention-executive dysfunction concept in, 324-325**
- historical background of, 324-325
 - hypotheses for, 324-326
 - neuropsychological studies of, in adults, 326
 - in children and adolescents, 325-326

Brain imaging, in ADHD, in adults, 336-338

- basal ganglia (striatum), 337
- dorsal anterior cingulate cortex, 336-337
- other subcortical and cortical regions, 337-338
- prefrontal cortex, 336
- in children and adolescents, 326-331
 - of basal ganglia (striatum), 329-330
 - of cerebellum, 331
 - of cerebral volume, total and lateralized, 327
 - of corpus callosum, 328-329
 - of dorsal anterior cingulate cortex, 328
 - of nucleus accumbens, 330
 - of prefrontal cortex, 328
 - of thalamus, 330
- hypothesized regions of interest for, 326-327
- structural and functional, in ADHD, 336-338
 - group averaged vs. individual, 339

Brain mapping, of executive functions and response inhibition, in ADHD, 273-274**Brain structure, in ADHD, longitudinal studies of, 338****Brown Attention Deficit Disorder Scales Diagnostic Form, for ADHD, 197-198****Buprenorphine, for opioid addiction, 638-639**

- Bupropion, for ADHD, in adults, 375-376
 in children, 375
 in children and adolescents, 116-117
 for depression, in children and adolescents, 116-117
 for smoking cessation, 632-633
- Bupropion SR, in ADHD, with substance use disorder, 293-294

C

- Calcium-channel blockers, for bipolar disorder, 168
- Cannabis use/abuse, co-occurring with depression, 669
 intoxication from, 100-101
 neuropsychological effects of, 101-102
- Cannabis withdrawal, affective and physical symptoms of, 666
 corticotropin-releasing factor systems in, 666-667
- Carbamazepine, for behavioral disorders, in children and adolescents, 162
 for bipolar disorder, in children and adolescents, 162
 dosing of, 163
 side effects of, 163
 in chronic PTSD, 443
 for comorbid substance abuse and bipolar disorder, 656
- Cardiac conduction, lithium and, in children, 159
- Catatonia, in depression, 28-29
 symptoms of, 28
- Catecholaminergic antidepressants, for ADHD, 292
- Catecholamines, in posttraumatic stress disorder, 54
- Catechol-o-methyl transferase (COMT) gene, in ADHD, 311
- Cerebellum, imaging studies of, in ADHD in children, 331
- Cerebrum, imaging of, in ADHD in children, 327
- Child abuse, in addiction psychiatry, 619-620
- Child custody, in addiction psychiatry, 617
- Children, disaster intervention with, after initial reaction to events, 483-484
 guidelines for, 478
- exposure to community disasters and violence, mental health programs for, **491-504**
 post-9/11, **491-504**
 case illustrations of relational PTSD, 478-480
 posttraumatic stress in, 474-476
 case of child-father shared nightmares, 478-480
 relationship with parent and, 477-478
 post-9/11 traumatic stress in, relational and developmental perspectives, **473-489**
 PTSD in, models of, 476
 relational and developmental perspective on, 477-478
 symptoms of, 476
 trauma and, parents and, 474
 reaction to, 494
 re-experiencing of event, 475
 separation from mother, 473-474
 trauma programs for, acceptability and feasibility of, to community, 495-496
 community-based, 496-499
 mentoring programs in, 500-501
 school-based, 497-498
 support in, 498
 traumatized, intervention with, parental participation in, 493-494
 mental health planning for, awareness of traumatized parenting, 492-494
 context sensitivity in, 495-497
 engaging community, families, and children in, 498-499
 enhancement of resilience in, 499-500
 flexibility and diversity of interventions in, 494-495
 gap between services available and used, 492
 zero to three, traumatic stress disorder in, diagnostic criteria for, 476-477
- Chloroform addiction, Glover and, 745
- Cholecystokinin, in disaster therapy, 445-446
 post-disaster, 445-446
- Cholinergic agents, for ADHD, 380-381

- Cholinergic interneurons, in striatum, 781
- Cholinergic neurons, acetylcholine from, 780
projections of, 780-781
- Cigarette smoking, ADHD and, 287, 290
substance use disorder and, 287
- Citalopram, in pediatric depressive disorders, 125, 126
- Clonidine, post-disaster, 437
- Clozapine, in bipolar disorder, in children and adolescents, 165-166
in Parkinson's disease, for drug-induced psychosis, 800-801
- Cocaine addiction, cognitive impairment from, 102
Halsted and, 745
pharmacotherapies for, adrenergic blockers, 641-642
dopaminergic medications, 640-641
gamma aminobutyric acidergic medications, 641
immunotherapies, cocaine vaccine, 642
withdrawal from, 102
- Cocaine use, myocardial infarction and, 681
nonischemic myocardial disease and arrhythmias, 681-682
- Cocaine vaccine, 642
- Cocaine withdrawal, anxiety and depressive-like symptoms in, 662-663
- Codeine, effects of, 690
- Cognition, correlation with regional blood flow in brain, 25-26
dysfunctional, in ADHD, 352
relationship with mood and movement, 31
- Cognitive-behavioral therapy, for alcohol abuse, 711
seeking safety therapy in, 718
for substance abuse disorders, 711
- Cognitive-behavioral therapy (CBT), for ADHD, in adults, 349-352
model of, 351-352
ongoing study at Massachusetts General Hospital, 354-358
published studies of, 352-354
Massachusetts General Hospital studies of, 354-358
studies of, 352-354
in pediatric depression, 138-139
adaptation of group format
comparison with interpersonal psychotherapy, 143
coping with depression course, 141
plus parents' group, 141
with emotion control, self-reinforcement, social problem solving, cognitive restructuring, 142
negative attributions/social problem solving focus in, 142
social skills training compared with supportive therapy in-142, 141
traditional form of, 142-143
post-disaster, 401
- Cognitive disorders, in Parkinson's disease, 799-800
- Cognitive enhancement therapy, in schizophrenia, 11
- Cognitive function, before and after trauma, and recovery from acute stress, 430-431
- Cognitive impairment, in Parkinson's disease, 799-800
in Shy-Drager syndrome, 807
in striatonigral degeneration, 807
in substance abuse, 97-109. See also *Substance abuse, cognitive impairment from.*
- Cognitive psychotherapeutic techniques, in post-disaster intervention, 404
- Cognitive remediation therapy, in schizophrenia, 11
- Combat fatigue, 408-409
- Combat trauma. See also *War psychiatry.*
cognitive reconstruction of, 409
prevention of, 409
- Community, disaster and, 391-392
trauma programs for children and, 495-496
- Comorbidity, of affective and substance use disorders, 649-659
nonpharmacologic treatments for, 651-652
pharmacologic and psychosocial treatment, 652

- psychotherapeutic/psychosocial strategies for, 651-652
 - of bipolar disorder and substance use disorders, 655-657
 - of major depression and substance use disorders, 652-654
- Competency(ies), civil, in addiction psychiatry, 614
- to stand trial, in addiction psychiatry, 618
- Comprehensive continuous integrated system of care (CCISC), characteristics of, 727-728
- for dual-diagnosis patients, 725-741
 - description of, 726-727
 - principles of treatment for, 728-730
- Conditioned fear response, amygdala in, in PTSD, 58-59
- in PTSD, amygdala and prefrontal cortexes in, 59
- Conduct disorder, in ADHD, auto accidents and, 235
- substance use disorder and, 290-291
- Confidentiality, of patients with substance-related disorders, in addiction psychiatry, 616-617
- Conners Adult Attention Deficit Hyperactivity Disorder Diagnostic Interview, in ADHD, 196
- Continuous Performance Test (CPT), in ADHD, for vigilance and sustained attention, 271
- Controlled Substance Act (CSA 1970), determination of control or decontrol in, 698-699
- factors in, 699-700
 - formal scheduling for drugs, basis of, 698-699
- Controlled substances, drug control policy and, 697
- increase in use of, 702
 - laws for, federal, 697-698
 - state, 698
- Controlled Word Association Test (COWAT), of associations and category fluency, in ADHD, 272
- Coping skills, in ADHD, 195
- Corpus callosum, morphometric studies of, in ADHD in children, 329
- Cortico-basal ganglionic degeneration, characterization of, 810-811
- dementia in, 811
 - personality and mood changes in, 811
 - sleep disorders in, 811
- Corticotropin-releasing factor, in stress response, 429-430
- Corticotropin-releasing factor antagonists, in disaster therapy, 440
- posttrauma, 440
- Corticotropin-releasing factor (CRF), in alcohol withdrawal, 665
- and anxiogenic effects in cocaine withdrawal, 663-664
 - in cannabinoid withdrawal, 666-667
 - in drug withdrawal, 661-662
- Corticotropin-releasing factor (CRF) systems, in anxiety disorders, 667-668
- Cortisol, in posttraumatic stress disorder, 55
- in PTSD, 434-435
- Countertransference, acute and chronic forms of, 572-573
- in disaster psychiatry, 571-587
 - among 9/11 therapists, 577-578
 - changes in feeling, 585
 - changes in thinking and work, 584-585
 - complementary to sadistic rage, 580-581
 - concordant to persevering anxiety, 579-580
 - grief and, 583-584
 - to the grotesque, 582-583
 - at ground zero, 578-579
 - to malevolent universe, 583
 - to perpetrator transference, 581-582
 - avoidant, 574-575
 - Buffalo Creek disaster, 571
 - effect on patient and therapist, 574
 - existential despair and, 576
 - forms of, 573-574
 - overinvolvement, 575
 - post-9/11, 571-572
 - pre-existing attitudes and biases and, 574-576
 - special features of 9/11
 - experience and, 576-577
 - as interactive process, 573
 - in trauma context, models of, 572
- Criminal population, addiction in, 620-621
- Crisis intervention, psychological debriefing and, 411

Critical incident stress debriefing (CISD),
412-413, 552
in disasters, 531

Critical incident stress management
(CISM), 552
teams in, Air Force, 461

Culture, definition of, 529-530
in disaster intervention, 523-524
with children, 528
cultural competency in,
527-528
research literature on, 524-526
meaning of, in disasters, 530
PTSD and, 526-527

Current Symptoms Scale-Self-Report Form,
Barkley, in ADHD, 196-197

Cylert. See *Femoline* (Cylert).

D

D-cycloserine, in schizophrenia, negative
symptoms, 12

Debriefing, 394, 411
accidents and, 414-415
across cultures, 417
adaptations of, 413-417
adverse effects of, 561
of children and adolescents, 416
clinical care and, 415
delayed model, 413
disasters and, 414
emergency service teams and,
407-408
evolution and current status, **407-423**
futures in, concepts in, 417
individual differences in,
418-419
mass violence and terrorism, 419
stressors in, 418
talking therapies in, 418
timeline for, 418
for whom, 418
group, post-disaster, 402
historical group model of, 413
with military personnel, 412
military teams and, 407-408
Mitchell model for, 412-413
multiple meanings of, 419
pathogenesis vs. salutogenesis
paradigm for, 417
psychological, early models, 412-413
workplace and, 415-416
World War I and, 408
World War II and, 408-409

Delirium, in Parkinson's disease, 799

Dementia, in cortico-basal ganglionic
degeneration, 811
in FTDP-17, 812
in olivopontocerebellar atrophy, 808
in Parkinson's disease, 799
in progressive supranuclear palsy,
809-810

Dementia with Lewy bodies (DLB),
characterization of, 804-805
depression in, 806
Parkinsonism co-occurrence in, 804
psychosis in, 805

Depression. See also *Bipolar disorder*; *Major depressive disorder*.
in ADHD, 191-192
in children and adolescents, alternative
therapies for, 128-129
antidepressants for, clinical
considerations with, 130
studies of, 120-121
bupropion for, 116-117
citalopram for, 125, 126
electroacupuncture for, 128
electroconvulsive therapy for,
129
fluoxetine for, 118-119, 122
future considerations in,
130-131
lithium for, 124-125, 127
mirtazapine for, 127
monoamine oxidase inhibitors
for, 115-116
nefazodone for, 124, 126-127
repetitive transcranial magnetic
stimulation for, 129
serotonin-selective reuptake
inhibitors for, 117, 122
somatic treatment of, **113-136**
St. John's Wort for, 128-129
trazodone for, 116
tricyclic antidepressants for,
113-114
vagus nerve stimulation for,
129-130
venlafaxine for, 124, 126
comorbid with substance use
disorders, 667-669
in dementia with Lewy bodies, 805
nonsomatic (psychosocial) treatments
of, **137-152**
in olivopontocerebellar atrophy,
808-809
in Parkinson's disease, 801-802
in pediatric population,
cognitive-behavioral therapies
for, 138-139
family therapy for, 140

- goal-oriented interventions with cognitive behavioral focus in, 144
 - interpersonal psychotherapy for, 139-140
 - multicomponent interventions in, problem of, 149
 - psychotherapy for, outcome studies of, 138
 - treatment approaches in, 138-140
 - school-based studies of, behavioral role playing and cognitive restructuring, 145-146
 - cognitive-behavioral self-control and behavior problem-solving training, 146
 - comparison of cognitive-behavioral therapy and relaxation techniques, 146
 - outcome assessments and self-reports in, 147
 - Primary and Secondary Control Enhancement Training, 147
 - response rates in, 147-149
 - social-competence training, 146-147
 - superiority of cognitive behavioral or relationship-focused therapies in, 147-148
 - treatment of, in clinically diagnosed samples, 140-145
 - guidelines for, 150
 - health services policy and, 149
 - interpersonal and social targets in, 145
 - psychotherapies in, efficacy of, 150-151
 - response to, 144
 - in undiagnosed symptomatic samples, 145-147
 - in progressive supranuclear palsy, 810
 - psychosocial treatments of, 137-152
 - in Shy-Drager syndrome, 807
 - unipolar, brain function in, 26
 - cognitive function in, 26
- Desipramine, for ADHD, in adults, 374-375
- in children and adolescents, 373-374
- for cocaine dependence, 654
- Dextroamphetamine, vs. amphetamine abuse liability, 294
- Dialectical-behavioral therapy (DBT), modified, group, in ADHD, 353-354
- Diminished capacity, in addiction psychiatry, 619
- Disability, in addiction psychiatry, 614-616
- Americans with Disabilities Act and, 615-616
 - definition of, 615
- Disaster psychiatry. See also *War psychiatry*.
- acute setting, psychopharmacology in, 425-458
 - collaboration in, with nonmental health agencies, 394
 - countertransference in, 571-587. See also *Countertransference*, in *disaster psychiatry*.
 - culture in, as concept, 529-530
 - diagnosis and, 530-531
 - role of, 530
 - and therapy and healing, 531-532
 - definition of, 392-393
 - elements of, 393-394
 - ethnocultural considerations in, 521-539. See also *Ethnocultural considerations*; in *disaster psychiatry*.
 - general, 391-406
 - goals of, 393
 - international, 505-519
 - interventions in, scientific information on, 394
 - mental health research and, after 9/11, 589-602
 - outreach practice model in, 394
 - preschoolers and, stress post-9/11, 473-489
 - psychiatric-legal considerations in, 559-570
 - systems issues in, emergency management response system, agency coordination in, 542
 - Federal Response Plan, 543-544
 - Incident Command System and, 542
 - Federal Emergency Management Agency, 543
 - federal resources and, 546-548
 - local programs, with federal support, 548
 - for psychiatrists, 541-558

- Disaster psychiatry (*continued*)
 public health system and emergency medical services, 543-545
 voluntary agency response, 549-553
 vs. trauma psychiatry, 393
- Disaster research, in determination of treatments, 593
 post-9/11, in city and surrounding areas, 593-594
 development of, 597-600
 comparison with Oklahoma City bombing research, 599
 confidentiality regulations and, 599-600
 institutional review boards and, 598-599
 populations for, 597-598
 turf issues in, 599
 exposure populations in, sampling of, 596-597
 screening of, 596
 in immediate vicinity, 593
 in PTSD, 595-596
 recommendations and policy for, 600
 post-disaster, exposure populations in, 594-595
 principles of, application of, 591-592
 value and role of, in mental health interventions, 590-591
- Disaster(s), acute impact, professional competition and conflict, 554
 psychiatrists' roles in, 554-555
 Buffalo Creek, 391-392
 clinical implications of, 401-404
 collective and individual trauma, normal vs. pathological responses, 523
 cultural competency guidelines in, 527-528
 as cultural encounters, 523-524
 culture in, 523-524
 definitions of, United Nations, 505-506
 World Health Organization, 391-392
 federal resources in, 544
 Centers for Disease Control and Prevention, 547
 Department of Veterans Affairs, 547
 National Center for Post-Traumatic Stress Disorder, 547
 National Disaster Medical System, 546
 National Institute of Mental Health, 547
 Substance Abuse and Mental Health Services Administration, 546-547
 global implications of, 522
 international. *See International disaster(s).*
 interventions in, indigenous partners in, 531-532
 research role in, 590-591
 local programs, community emergency response teams, 548
 Medical Reserve Corps, 548
 Metropolitan Medical Response System, 548
 man-made, omission vs. commission in, 397-398
 vs. natural events, 392, 397, 398
 mental health aftermath of, 395-398
 anxiety problems, 395
 major depression, 395
 posttraumatic stress disorder following, 395-396
 substance abuse, 395-396
 natural vs. man-made, 506
 psychiatrist role in, consultation with public health officials, 553-554
 planning emergency management, 553
 psychopharmacology in, 425-458, 435
 anticonvulsants, 443-444
 antipsychotics, 442-443
 β -adrenergic blockers, 435-437
 benzodiazepines, 437-439
 cholecystokinin, 445-446
 corticotropin-releasing factor antagonists, 440
 ethanol, 444-445
 glucocorticoids, 440-441
 neuropeptide Y, 445
 opiate agonists, 441
 α_2 -receptor agonists, 437
 sedative hypnotics, nonbenzodiazepine, 439
 serotonin reuptake inhibitors, 441-442
 recovery from, long-term treatment, 555
 short-term interventions, 555-556
 special populations in, 396
 survivors' psychological reactions, 396-397
 terrorism as, 398-401. *See also Terrorism.*

- voluntary agency response in,
 - American Group Psychotherapy Association, 552
 - American Psychiatric Association, 550-551
 - American Psychological Association, 550-551
 - American Red Cross, 549
 - American Red Cross Disaster Mental Health Services, 549-550
 - Disaster Psychiatry Outreach, 551
 - International Critical Incident Stress Foundation, 551-552
 - International Society for Traumatic Stress Studies, 552-553
 - National Alliance for the Mentally Ill, 551-552
 - National Mental Health Association, 552
 - National Organization for Victim Assistance, 540
 - National Voluntary Organizations Active in Disaster, 549
- Disaster worker, culture and, 529-530
- Disinhibition, in ADHD, 324-325
 - in children and adolescents, antidepressant-induced, 130
- Disruptive behaviors, antidepressant-induced, 130
- Dissociation, neurobiology of, 432
 - N-methyl-D-aspartate receptor in, 432
 - in posttraumatic stress disorder, 60-61
 - as risk factor for PTSD, 432
 - as stress response, 430
- Disulfiram, for alcohol addiction, 633-634
 - for cocaine addiction, 640-641
- Divalproex, for comorbid substance abuse and bipolar disorder, 656
- Divalproex sodium (valproate sodium). See *Valproate sodium*.
- Donepezil, for Parkinson's disease, 799
- Dopamine, endogenous, anatomy and physiology of, 778-780
- Dopamine receptor gene(s), in ADHD,
 - DRD4, 308-309
 - DRD5, 311
 - in gene-brain hypotheses, DRD4, 338-339
- Dopaminergic medication, cognitive impairment with, 799
 - for Parkinson's disease, psychosis with, 800
- Dopaminergic neurons, activity of, 778
- Dopamine system, in ADHD, 307-311
- Dopamine systems, mesocortical, 780
 - mesolimbic, 779
 - nigrostriatal, 779
- Dopamine transporter gene (DAT), in ADHD, 310-311
- Dorsal anterior cingulate cortex (dACC), neuroimaging studies of, in ADHD,
 - in adults, 336-337
 - in children and adolescents, 328
- Dorsal lateral prefrontal cortex (DLPFC), disruptions in, cognitive impairment and, 24-25
- Driving, alcohol- and drug-related offenses, in addiction psychiatry, 620
- Driving performance, in ADHD, in adults with ADHD diagnosis in childhood, 252-253
 - impaired and adverse, behavioral therapy for, 253-254
 - stimulants for, 254-255
 - treatments for, 253-255
 - operational level of, 243
 - strategic level of, 237-238
 - studies of, 240-241, 243
 - simulators in, 238-239, 242, 244-246
 - substance use impact on, 227-230, 243-246
 - tactical level of, 236-243
 - anger, hostility, aggression and, 250-252
 - cognitive abilities for, 240-241
 - current models of, as multi-dimensional activity (Michon), 237-239
 - operational level in, 236
 - strategic level in, 237-238
 - tactical level in, 236-238
 - skill-rule-knowledge (Rasmussen), 238-239
- Drug dependence, neurobiological mechanisms in, 661-662

- Drug use/abuse, in adults with ADHD,
 impact on driving, 243-246
 during critical periods of brain growth,
 105
 potential for abuse, 699
 as threat to public health, 687
- Drug withdrawal, duration of, 693
 neuronal substrates in, for
 amphetamine, 664-665
 for cannabinoids, 666-667
 for cocaine, 662-664
 from opiates, 693-694
- d-Serone, in schizophrenia, for negative
 symptoms, 12
- Dual-diagnosis disorders, categorizing of,
 model for, 728
- Dual-diagnosis integrated treatment
 (IDDT), 725-726
- Dual-diagnosis patient, assertive
 community treatment for, 711-712
 behavioral interventions for, **707-723**
 comprehensive continuous integrated
 system of care for, **725-741**
 accomplishments of, 739
 case management in, 729
 clinical outcomes for, 730
 diagnosis in, 728-729
 disease and recovery model in,
 730
 implementation of, steps in,
 731-736
 interventions in, 730
 primacy of each disorder in,
 729-730
 project descriptions and
 outcomes, Manitoba,
 Canada, 737-738
 New Mexico, 736
 San Diego, 738-739
 Vermont, 737
 treatment relationships in, 729
 employment and housing for,
 712-714
 individual placement and support
 model for, 713-714
 epidemiology of, 707
 family interventions in, 714-716
 housing needs of, 715
 individual interventions for,
 cognitive-behavioral therapy,
 711
 motivational enhancement, 710
 residential rehabilitation programs for,
 713-715
 therapeutic communities, 714,
 716
 treatment models for, emergency,
 709-710
 four stages of therapeutic process
 model, 709
 parallel model, 708
 treatment of, coerced intervention,
 719-720
 family interventions in, 714-716
 group therapy for, 717
 involuntary intervention in,
 719-720
 multiple family groups in,
 716-717
 persuasion groups for, 717
 seeking safety therapy in, 718
 social skills groups for, 718
- Duty to protect or warn, in addiction
 psychiatry, 617
-
- ## E
- Eating disorders, in Parkinson's disease, 803
- Ecstasy, cognitive impairment from, 103
 neurological damage from, 103
- Elderly, depression in, comorbid with
 alcohol abuse, comorbid, 668-669
 schizophrenia in, cognitive impairment
 and, 5-6
- Electroacupuncture, in pediatric depressive
 disorders, 128
- Electroconvulsive therapy (ECT), in bipolar
 disorder, adults, 167
 children and adolescents, 167
 for depression, in Parkinson's disease,
 802
 in pediatric depressive disorders, 129
- Encephalitis lethargica (von Economo
 encephalitis), 187, 205
- Ethanol, in disaster therapy, 444-445
- Ethnocultural considerations, in disaster
 psychiatry, **521-539**
 cultural competency guidelines
 and, 527-528
 culture as concept in, 529-530
 disaster worker and, 522,
 528-529
 in PTSD, 525-527
 research needs, 534-535
 response to
 psychopharmacological
 agents, **521-539**
 training needs, 534
 in international disaster interventions,
 507-509

Evidence-based best practice. See also *Best practice*.

in dual-diagnosis treatment, 735

Executive function/executive dysfunction, in ADHD, 83-96, 191, 262-263. See also *Attention deficit hyperactivity disorder (ADHD)*.

in children, 274

in bipolar disorder, 23

in borderline personality disorder, 68

deficits in ADHD, driving and, 241

definition of, 84

in depression, 26

in mood disorders, structural and functional abnormalities of brain regions in, 25

in obsessive-compulsive disorder, 38-39

Expert witnesses, in forensic work, liability of, 624

Eye-movement desensitization and reprocessing, 394

F

Family, in dual-diagnosis treatment, 714-717

Family behavioral therapy, in dual disorder treatment, 714-716

Family therapy, in pediatric depression, 140

Fear, as conditioned response, memory in, 431-432

in posttraumatic stress disorder, 58-59

in face of ongoing threat, 403-404

Fentanyl, in operating room air, 749

Fetal alcohol syndrome (FAS), 105

Fetus, in addiction psychiatry, 619-620

Flashbacks, adaptive and pathological significance of, 431

Fluoxetine, in children and adolescents, studies of, 118-119

Fluvoxamine, in pediatric depressive disorders, studies of, 121, 122-123

Frontal-striatal-thalamic-cortical (FSTC) circuitry, in attention-deficit/hyperactivity disorder, 86-88

Fronto-striatal circuits, of basal ganglia, in attentional set shifting, 765
circuit-specific functions of, 763-768

in executive function, 765

in goal-directed behaviors, 768

in motivational and affective information, 766

motor, 764

oculomotor, 764-765

parallel segregated or functionally interacting views, 768-770

in reversal learning and extinction, 767-768

in reward processing, 766-767

in social behavior and empathy, 765

structure of, 760-764

in working memory, 765

Fronto-striatal system, in executive function deficits, 39

FTDP-17, characterization of, 811-812
dementia in, 812

Functional neuroimaging studies, in attention disorder/hyperactivity disorder, 89-90
with cognitive challenges, in mood disorders, 25-26
in obsessive-compulsive disorder, frontal-striatal abnormalities in

G

Gabapentin, in children, 164

Gamma aminobutyric acid (GABA), in basal ganglia circuitry, 781

Gender, effect of, on ADHD, 225-232
on neuropsychological abnormalities, in ADHD, 268-270

Genetics, of ADHD, adoption studies of, 305-306
in adulthood, 313-315
in childhood, 304-313
family studies of, 304
molecular studies of, 306-313
candidate gene approach in, 307-313
genome scan approach in, 307
twin studies of, 304-305

Glucocorticoids, in disaster therapy, 440-441
posttrauma, 440-441

Glutamate, action of, 781-782
within cortico-basal ganglia loops, 782
in stress response, 428

- Good Samaritan laws, 560
- Grief, of therapists, in 9/11 disaster, 583-584
- Grief counseling, in psychological trauma, 410
- Group therapy, for dual-diagnosis patient, 717-718
- Guanfacine, post-disaster, 437
- Gulf War Syndrome, 408-409

H

- Hallucinogen abuse, flashbacks from, 104
 - neurotoxicity of, 104
- Harvard Trauma Questionnaire, cross-cultural versions of, 509
- Health-seeking behaviors, of disaster victims, 529
- Heroin use, lung function in, 684
- Hippocampus, anatomy of, in
 - posttraumatic stress disorder, in declarative and fragmented memory, 54-55
 - disruptions in, cognitive impairment and, 24-25
 - in posttraumatic stress disorder, declarative memory impairment and, 56
 - traumatic amnesia and, 61-62
 - in stress reactions, 427-428
 - and traumatic memories, 431
- Hostages, reintegration into society, 464-465
 - Stockholm effect in, 399
- Hydrocortisone, posttrauma, 440-441
- Hyperactivity/impulsivity, in ADHD, 189-191, 227-228, 230
 - auto accidents and, 234-235
- Hyperarousal, adrenergic mechanisms in, 433
- Hypomania, in children and adolescents, antidepressant-induced, 130
- Hypothalamic-pituitary-adrenal axis, hippocampus and, 435
 - in PTSD, 434
- Hypothalamus-pituitary-adrenal (HPA) axis, in anxiety disorders, 667-668

I

- Immunotherapy(ies), for cocaine addiction, 642
- Inattention, in ADHD, 189-191, 227-228, 230
 - auto accidents and, 234
- Individuals with co-occurring psychiatric and substance disorders (ICOPSD). See *Dual-diagnosis patient*.
- Infants, disaster intervention with, after initial reaction to events, 483-484
 - posttraumatic stress in, 475
- International disaster(s), capacity building in, mental health in primary care, 512-513
 - interventions in, cross-cultural
 - difficulties in, 508-509
 - direct, community-based, 511
 - goals of, 508
 - indirect efforts, psychosocial impact of, 510-511
 - international relief community in, 509-510
 - needs for, evidence-based
 - literature, 506-507
 - self-reflection, 507-508
 - for relief workers, 516
 - work with local leaders in, 512
- mental health in, in community, group, and individual settings, 513-515
 - individual, 514-515
- toxic, Bhopal, 515-516
 - Chernobyl, 516
 - psychological impact of, 515-516

- Interpersonal psychotherapy (IP), in
 - pediatric depression, 139-140
 - comparison with clinical monitoring, 143-144

- Involuntary commitment, in addiction psychiatry, 613-614

- Involuntary intervention, dual-diagnosis patient and, 719-720

J

- Jails and prisons, addiction treatment in, 621

K

- Kiddie-SADS (K-SADS) Diagnostic Interview Section, for ADHD, 197

L

Lamotrigine, in bipolar disorder, in children
and adolescents, 163-164
in chronic PTSD, 443-444

Learning disabilities, in ADHD, in
adolescents, 266
in children, 264-266
brain abnormalities and,
332
relationship with
neuropsychological
dysfunctions, 266-267
definitions of, 265-266, 332

Levomethadyl acetate (LAAM),
for opioid addiction, 637-638

Liability, professional, in addiction
psychiatry, 616
of rescuer, in emergency assistance,
559-560

Light therapy, in pediatric depressive
disorders, 125, 127-128

Lithium, in adults, for manic and depressive
episodes, 154-155
for bipolar disorder, response to, in
substance abuse disorders, 655
in children and adolescents, 155
adverse effects of, 159
with bipolar disorder and
substance dependence, 156
controlled studies of, 156-157
dosing of, 157
drug interactions with, 159
duration of treatment, 157-158
open studies of, 156-157
pharmacokinetics of, 160
predictors of response and
resistance to treatment,
159-160
side effects and, common, 158
myoclonus from, 30
in pediatric depressive disorders,
124-125, 125, 127

Locus coeruleus, anatomy of, 51, 53
in posttraumatic stress disorder,
hyperarousal and, 53-54
memory consolidation and, 54

M

Magnetic resonance imaging (MRI),
functional, in ADHD, 89-90

Major depressive disorder. See also
Depression.
alcoholism in, pharmacotherapies for,
653-654

cocaine dependence and,
pharmacotherapies for, 654
criteria for, DSM-IV, 19-20
opiate dependence in, cocaine
dependence and, 654
in Parkinson's disease, 801-802
post-disaster, long-term aftermath of,
403
research findings and, 592
substance use disorders comorbid in,
652-654

Mania, in children and adolescents,
antidepressant-induced, 130
in Parkinson's disease, 802

Massachusetts General Hospital, ADHD
studies, 225-232, 378-381
methylphenidate in, 362-367
cognitive-behavioral therapy study,
for ADHD in adults,
354-358
distractibility in, 356
dysfunctional thoughts in,
356-357
organizational and planning
skills in, 354-355
results of, 357-358
targets of, 3454-357
treatment protocol in,
357
motivational interviewing
techniques in, 355-356
problem-solving training in,
355-356

Memory, executive function disturbances
and, 39-40
in mood disorders, loss of,
23-24
in posttraumatic stress disorder,
declarative and fragmented,
54-55
structural and functional
abnormalities of brain regions in,
25

Mental health professional, post-disaster,
knowledge of psychological and
physical effects of weapons of mass
destruction, 402
as media advisor, 402-403

Mesocortical dopamine system, 780

Mesolimbic dopamine system, 779-780

Methadone, effects of, 690
for opioid addiction, 636-637

Methamphetamine, cognitive impairment
from, 102-103

- Methylphenidate (MPH), for ADHD, in adults, 362-367
- National Institute of Mental Health study of, 367-368
 - in children and adolescents vs. in adults, 362
 - for driving performance, 254-255
 - Massachusetts General Hospital study of, 362-367
 - design and method in, 363-364
 - inclusion and exclusion criteria for, 362-363
 - response to treatment in, 365-367
 - results in, 364-366
 - in cocaine abuse/dependence and ADHD, 292-295
- Military issues. See also *War psychiatry*.
in psychological trauma of war, 459-471
- Mirtazapine, in comorbid alcoholism and depression, 654
in pediatric depressive disorders, 127
- Monoamine oxidase inhibitors (MAOIs), for ADHD, 376-377
in children and adolescents, 115-116
- Mood, in cortico-basal ganglionic degeneration, 811
- Mood-cognition relationship, 20, 31
- Mood disorders. See also *Bipolar disorder*; *Depression*; *Major depressive disorder*.
in ADHD in children, brain abnormalities and, 332-333
brain in, functional neuroimaging of, with cognitive challenges, 25-26
regional blood flow in, and cognition, 25-26
structural and functional abnormalities of, 24-27
characterization of, 19-20
cognitive and neurological impairment in, 19-36
cognitive deficits in, 21-24, 22-23
across states, 22
attention/working memory, 22
in bipolar disorders, 26
in unipolar depression, 26
incidence of, 19
limbic region in, functional abnormalities in, 24
neuroimaging in, 20
neurological deficits in, 27-31
across mood states, 28
catatonia, 28-29, 28-39
myoclonus, drug-induced, 29-30
parkinsonism, 30-31
psychomotor agitation, 28
psychomotor retardation, 27-28
tardive dyskinesia, 30
relationships in, among mood, cognition, and movement, 31
- Mood stabilizers, for comorbid alcoholism and bipolar disorder, 655-656
- Morphine, effects of, 690
- Morphine addiction, Halsted and, 745
- Morphine sulfate, posttrauma, 441
- Movement, relationship with mood and cognition, 31
- Multiple system atrophy (MSA), diagnostic criteria and features of, 806
Parkinsonism in, 806
types of, 806
- Myoclonus, drug-induced, in mood disorders, 29-30
obsessive-compulsive disorder and, 40
-
- N**
- Naltrexone, for alcohol addiction, 634-635
for opioid addiction, 639
- Nefazodone, in pediatric depressive disorders, 124, 126-127
- Neonates, maternal opiate use and, 684
- Neuroimaging, in ADHD, 88-91
functional, 89-90
neurochemical, 90
structural, 88
in mood disorders, 20
in obsessive-compulsive disorder, 42-43
- Neuroleptics, in schizophrenia, brain structure and, 7-8
tardive dyskinesia from, 30
- Neuropeptide Y, in disaster therapy, 445
post-disaster, 445
- Neuropsychiatry, of Parkinson's disease and related disorders, 797-821
- Neuropsychological dysfunction, in ADHD. See also *Learning disabilities*.
in adolescents, 264
in adults, 270-273
tests of, 271-273

- in children, 263
- gender effects on, 268-270
- learning disabilities in, 264-267
- psychiatric comorbidity and, 264
- brain structure and function
 - relationship to, in ADHD, 273-274
- heterogeneity of ADiD and, 267-268
- Neuropsychological function, in ADHD, in adults, **261-282**
 - future research in, 274-275
 - future research directions for, genetics, 274-275
 - integration of models in, 275
 - longitudinal study, 274
 - significance of deficits in, 275
 - treatment approaches, 275
- Nicotinic treatment, for attentional disorder, in schizophrenia, 12
- Nicotine replacement therapy, for smoking cessation, 630-631
- Nightmares, posttrauma, shared, case illustration of, 478-480
- Nigrostriatal dopamine system, 779
- Nimodipine, in cycling affective disorder, 168
- N-methyl-D-aspartate (NMDA) antagonists, during trauma, 432
- N-methyl-D-aspartate (NMDA) receptor, dissociation and, 432
- Noradrenergic agents, for ADHD, 292
- Noradrenergic system, sensitization of, in PTSD, 433-434
- Norepinephrine, in posttraumatic stress disorder, 54
 - in stress response, 429
- Nortriptyline, for smoking cessation, 632
- Novel anticonvulsants, for bipolar disorder, in children and adolescents, 163-164
- Nucleus accumbens, structure and function of, in ADHD in children, 330

O

- Obsessive-compulsive disorder (OCD), cognitive and neurobiological findings in, **37-47**
 - neurobiological findings in, 40-41
 - neurological soft signs in, 41
 - interpretation of, 42
 - neuropsychological findings in, executive function deficits, 38-39
 - nonverbal memory impairment, 38
 - visuospatial deficits, 37-38
 - treatment of, functional neuroimaging findings following, 42-43
 - SSRIs in, 42
- Olanzapine, in bipolar disorder, 166-167
 - in dementia with Lewy bodies, 805
 - in Parkinson's disease, 801
 - in prepubertal children, 167
- Oligopontocerebellar atrophy (OPCA), dementia in, 808
 - depression in, 808-809
 - psychosis in, 808-809
 - sleep disorders in, 809
- Omega-3 fatty acids, for bipolar disorder, 168
- Opiate agonists, in disaster therapy, 441
 - posttrauma, 441
- Opiates. See also *Prescription opiates*,
 - addiction to,
 - actions of, 689-690
 - addiction to, **687-706**
 - in anesthesia, addiction to, 744-749
 - detection of in operating room air, 749
 - anesthesiologist exposure to, in operating room air, 747-749
 - effects of, 690-692
 - intoxication from, criteria for, 694-695
 - effects of, 693-694
 - medical uses of, 690-692
 - mental and motor impairments from, 693
 - mu receptor and action of, 689-690
 - specific drug 689s
 - tolerance to, 692-693
 - types of, 689
 - withdrawal from, duration of, 693
 - pharmacologic therapies for, 694
 - symptoms of, 694
- Opiate use/abuse. See also *Prescription opiate addiction*,
 - and hepatitis C, 683-684
 - and HIV, 683

- Opiate use/abuse (*continued*)
 overdose and, 683
- Opioid addiction, pharmacotherapies for,
 buprenorphine, 638-639
 levomethadyl acetate, 637-638
 methadone, 636-637
 naltrexone, 639
 opioid agonists, 636-639
 opioid antagonists, 639
- Opioid agonists, for opioid addiction,
 636-639
- Opioid antagonists, for opioid addiction,
 639
- Opioid dependence, pharmacotherapies for,
 629-630
- Opium use, laryngeal cancer from, 684
- Orbito-frontal cortex (OFC), dysfunction
 of, in obsessive-compulsive disorder,
 40, 43
 lesions in, and cognitive deficits in
 obsessive-compulsive disorder,
 39
- Oxycodone, effects of, 690-691
-
- P**
- Pain, chronic nonmalignant, management
 of, professional liability in, 616
- Pallidotomy, for Parkinson's disease, effects
 of, 799-800
- Pallidum, inputs and internal organization
 of, 758-759
 output from, 759
- Panic attacks, in Parkinson's disease, 802
- Paraphilias, in Parkinson's disease, 804
- Parents, education in trauma and PTSD,
 484
 participation in PTSD intervention,
 487
 posttraumatic stress in, effect on child,
 492-493
 relationship with preschooler
 and, 477-478
 trauma of child and, 474
- Parkinsonism, neuroleptic induced, 30-31
- Parkinson's disease, alcohol, substance
 abuse, and eating disorders, 803
 anxiety in, 803
 characterization of, 798-799
 cognitive disorders in, 799-800
 depression in, major, 801-802
 executive dysfunction in, 765-766
 fronto-striatal circuits in, 768
 mania in, drug-related, 801
 neurodegenerative proteinopathies in,
 797-798
 paraphilias in, 804
 pathophysiology of, glutamate in, 782
 psychosis in, drug-induced, 800
 treatment of, 800-801
 and related disorders, neuropsychiatry
 of, 797-821
 sexual disorders in, 804
 sleep disorders in, 803-804
 treatment of, 798
- Paroxetine, in pediatric depressive
 disorders, studies of, 120-121, 123
- Pemoline (Cylert), for ADHD, in adults,
 367-369
- Personality changes, in cortico-basal
 ganglionic degeneration, 811
 in progressive supranuclear palsy, 810
- Phenytoin, in stress prevention, 444
- Physicians, with addictive disorders,
 reporting requirements for, 623-624
 prescribing practices of, attitudes in,
 703-704
 factors in, 704
 risk for addiction in, 744-745
 historical examples of, 745
- Positron emission tomography (PET), in
 ADHD, 89
- Posttraumatic growth, 523
- Posttraumatic stress disorder (PTSD),
 amygdala in, physiological reactivity
 in, 59
 positron emission tomography
 study findings, 59
 in children, developmental issues and
 symptoms, 592
 conditioned responses in, 432
 controversies surrounding, 50
 cost to individual and society, 49-50
 cultural variations in, literature on,
 525-526
 culture and, 526-527
 development of, theories of, 430
 diagnostic criteria for, DSM-IV,
 52-53
 disasters and, long-term aftermath of,
 403
 etiology of, cortisol in, 434-435
 hippocampus in, anatomy of, 54-55
 cortisol effect on, 55-56
 and declarative memory
 impairment, 56
 function in memory, 55

- and traumatic amnesia, 56-57
 - volume reduction issue in, 55-56
 - Jocus coeruleus in, anatomy of, 51, 53
 - and hyperarousal symptoms, 53-54
 - and memory consolidation, 54
 - need for balance of vulnerability and responsibility in, 62-63
 - neurological change and clinical correlates, 49-65
 - noradrenergic system in, sensitization of, 433-434
 - post-disaster, 395-396
 - medical model approach to, 595
 - research findings, 591-592
 - risk factors for, PTSD in childhood, 474
 - signs and symptoms of, 51
 - startle response in, amygdala in, 58
 - thalamus in, anatomy of, 59-60
 - and attentional bias, 61
 - and dissociation, 60-61
 - and traumatic amnesia, 61-62
 - Vietnam War and, 410-411
- Prazosin, post-disaster
- Prefrontal cortex, imaging studies of, in ADHD in children, 328
- medial, in stress reactions, 428
- Pregnancy, in addiction psychiatry, 619-620
- Preschool children, disaster intervention with, after initial reaction to events, 483-484
- Prescription monitoring programs, prescription form for schedule II drugs, 701-702
- public and private reactions to, 702-703
 - studies of, 703
- Prescription opiates. See also *Controlled substances*, *Opiates*.
- addiction to, 687-706
 - drugs of abuse in, 688
 - in health care professionals, 689
 - opiate actions and, 689-690
 - physician identification, diagnosis, and referral for, 695-696
 - populations at risk, 688
 - research needed for, 704
 - treatment of, 696
 - benefits and risks of, 690
 - controlled substance policy and laws and, 697-698
 - market profits from, 688
 - medical uses of, 689-692
 - physician attitudes and practices regarding, 696-697
 - physicians as source of problems and solutions, 695-696
 - scheduling for controlled substances, 698-701
- Preventive psychiatry, 409-410
- Prison, addiction treatment in, 621
- Prisoners of war, persons at risk, Survival, Evasion, Resistance, and Escape training for, 464
- reintegration into society and, 465
- Professionals, with addictive disorder, fitness to practice and, 622
- drug testing of, 623-624
 - impairment and fitness to practice, 622-623
 - tissue testing of, 623-624
- Progressive supranuclear palsy (PSP), anxiety in, 810
- characterization and diagnosis of, 809
 - dementia in, 809-810
 - depression in, 810
 - personality changes in, 810
 - psychosis and bipolar disorder in, 810
 - sleep disorders in, 810
- Propofol, in operating room air, 749-750
- Propranolol, in prevention of PTSD, 436-437
- re-emergent, 436-437
- Proton magnetic resonance spectroscopy, in ADHD, 90
- Proximity, immediacy, expectancy, simplicity (PIES), in combat psychiatry, 460
- Psychiatric disorders, co-occurrence with substance use disorders. See also *Dual-diagnosis patient*.
- substance abuse in, for self-medication, 669
- Psychiatric-legal issue(s), in disaster mental health assistance, accuracy of record keeping, 564-567
- causation and, 566
 - diagnoses and, 565-566
 - diagnosis vs. disability and, 565
 - advice giving and liability, 563-564
 - compensation-related paperwork, 567-568

Psychiatric-legal (*continued*)

- confidentiality and media, 562-563
 - diagnosis without corroboration, 566-567
 - documentation, 562
 - for compensation of survivors, 564
 - litigation effect on mental state and treatment, 568-569
 - malingered, 568-569
 - report preparation, 568
 - role maintenance, 563-564
 - secondary gain, 569
 - in emergency assistance, adverse effect of treatment and, 561
 - doctor-patient relationship in, 559-560
- Psychodynamic techniques, in post-disaster intervention, 404
- Psychoeducation, in post-disaster intervention, 404
- Psychological trauma, civilian, victim groups and, 409
- debriefing and, early models, 412-413
 - historical perspective, 411-412
 - grief counseling in, 410
 - in war, 407-409
- Psychomotor retardation, in mood disorders, 27-28
- Psychosis, in dementia with Lewy bodies, 805
 - in olivopontocerebellar atrophy, 808-809
 - in Parkinson's disease, 800-801
 - in progressive supranuclear palsy, 810
- Psychosocial treatments, for ADHD, in adults, 349-360
 - cognitive approaches, 350-358
 - dialectical-behavioral therapy in, 353-354
 - for comorbid substance abuse and bipolar disorder, 656-657
- Psychotherapy, cognitive-behavioral, 138-139, 141-143
 - for comorbid depression and substance abuse, 654
 - individual and group, post-disaster, 401-402
 - interpersonal, 139-140
 - outcome studies of, 138

Q

- Quetiapine, in dementia with Lewy bodies, 805
- Quetiapine fumarate, in bipolar disorder, single case report in child, 166

R

- Relapse prevention, in substance abuse disorders, 627-648
- Repetitive transcranial magnetic stimulation, in pediatric depressive disorders, 129
- Residential programs, for dual-diagnosis patients, 713-715, 735
- Resilience, in disaster, 591
 - sources of, 500
 - of traumatized children, enhancement of, 499-500
- Risperidone, in bipolar disorder, reduction of manic, psychotic, aggressive symptoms, 166
- Rivastigmine, in dementia with Lewy bodies, 805, 806
- Road rage. *See Anger, hostility, and aggression.*
- in ADHD, 250-252

S

- Sanity, in addiction psychiatry, 618-619
- Schedule II drug, criteria for, 700
- Schedule III drug, criteria for, 701
- Schedule IV drug, criteria for, 701
- Schizophrenia, brain hypertrophy in, medication-induced, 7
- cognition and brain structure in, 1-18
 - in elderly, cognitive deterioration in, 5-6
 - neuroanatomic abnormalities in,
 - caudate size, 3
 - in cellular architecture, 4
 - enlarged ventricles, 3, 6
 - left hemisphere, 4
 - thalamic, 4
 - neurocognition in, with aripiprazole relative to olanzapine, 10-11
 - atypical antipsychotics and, 9-10
 - conventional antipsychotics and, 9
 - medication effects on, 9-12

- risperidone relative to conventional neuroleptics, 11
- neurocognitive deficits in, 1-3
 - according to clinical symptomatology, 2-3
 - course across lifespan, 4-6
 - disorganization and, 2-3
 - episodic memory and vigilance, 3
- neurodegenerative model of, 6-7
 - volume reduction of gray matter, 7
- neurodevelopmental model of, 8-9
 - versus neurodegenerative, 9
- signs and symptoms of, 1
- Sedative hypnotics, in disaster therapy, 439
 - posttrauma, 439
- Seeking safety therapy, for dual-diagnosis patient, 718
- Selective serotonin reuptake inhibitors (SSRIs). *See Serotonin reuptake inhibitors.*
- Self-assessment, of driving performance, in ADHD, 246-249
- Self-medication, in co-occurrence of psychiatric and substance use disorders, 669, 707
- Sensitization, opiate addiction and, 745, 747-748
- Separation anxiety, 494
- Serotonergic agents, for alcohol addiction, 635
- Serotonergic system, in ADHD, 312-313
- Serotonin, in basal ganglia, 782
- Serotonin reuptake inhibitors. *See Selective serotonin reuptake inhibitors (SSRIs).*
- Serotonin reuptake inhibitors (SSRIs), in children and adolescents, 117, 122
 - in disaster therapy, 441-442
 - in major depression in alcoholics with 5-HT abnormalities, 653
 - in obsessive-compulsive disorder, 42
 - in Parkinson's disease, 802
 - PTSD and, neurobiology of, 441-442
- Sertraline, in pediatric depressive disorders, studies of, 120, 123-124
- Sexual disorders, in Shy-Drager syndrome, 808
- Shell shock, 408
- Shy-Drager syndrome, cognitive disorders in, 807
 - depression in, 807
 - sexual disorders in, 808
 - sleep disorders in, 808
- Single photon emission CT, in ADHD, 89
- Sleep disorders, in cortico-basal ganglionic degeneration, 811
 - in olivopontocerebellar atrophy, 809
 - in Parkinson's disease, 803
 - in progressive supranuclear palsy, 810
 - in Shy-Drager syndrome, 808
- Smoking, addiction to nicotine in, 676
 - prevalence of, 675
- Smoking cessation, pharmacotherapies for, 627-633
 - bupropion, 632
 - clonidine, 632-633
 - nicotine replacement therapy, 630-631
 - nortriptyline, 632
- SNAP-25 transgene, in ADHD, 312
- Social skills groups, for dual-diagnosis patient, 718
- Soft signs, in obsessive-compulsive disorder, 41-42
 - and in schizophrenia, 42
- St. John's Wort (*Hypericum perforatum*), in pediatric depressive disorders, 128-129
- Startle response, amygdala in, in posttraumatic stress disorder, 58
- Stimulant therapy, for ADHD, 292
 - in adults, 361-372
 - substance use disorder risk and, 286
 - cognitive impairment from, 102-103
- Stress response, neurotransmitters in, corticotropin-releasing factor, 429-430
 - glutamate, 428
 - norepinephrine, 429
- pathological, cognitive changes and, 430-432
 - memory and fear conditioning in, 431-432
- to traumatic events, amygdala in, 426-427
 - hippocampus in, 427-428
 - medial prefrontal cortex in, 428
 - neurobiological basis of, 426-428
- Striatonigral degeneration (SND), 807
- Striatum, corticostriatal input to, 757

Striatum (*continued*)

- disruptions in, cognitive impairment and, 24-25
- efferents of, 758
- locus coeruleus projections to, 758
- mesencephalostratial input to, 757-58
- midbrain Raphe nuclei projections to, 758
- organization of, 756-757
- thalamostriatal input to, 758

Stroop task, test of inhibition, in ADHD, 271

Substance abuse, cognitive impairment

- from, in adolescence, 105
- alcohol, 99-100
- amphetamine/
 - methamphetamine, 102-103
- cannabis, 100-102
- cocaine, 102
- ecstasy, 103
- hallucinogens, 104
- Korsakoff's dementia, 100-101
- multiple drug dependence and, 104-105
- prenatal exposure and, 105
- stimulants, 102-103
- treatment implications of, 105
 - for goals and choice of treatment, 106
 - for program design, 106-107
 - screening for, 106
- cognitive impairment in, **97-109**
- disorders consequent to, 97-99
- in Parkinson's disease, 803
- polydrug, neuropsychological deficits with, 104-105
- post-disaster, 592-593
- substance-induced disorders from, 97-99

Substance use disorder (SUD), in ADHD, **283-301**

- in adolescents, 284
- in adults, 284
- auto accidents and, 235
- diagnosis of, 291-292
- familial relationships between, 288-289
- gender influence on, 227-230
- impact on driving, 243-246
- literature review of, 289-290
- longitudinal studies of, 287
- nonstimulant agents for, 294
- onset of, 288-289
- parental, 286
- pathways in, 287-288
- remission from, 288

- risk factors for, 285-287
- treatment of, 291-295
- cognitive-behavioral therapy for, 711
- comorbidity of psychiatric disorders and, 667-668
- co-occurrence with psychiatric disorders. *See also Dual-diagnosis patient.*
- co-occurring affective disorders and, **649-659**
- in criminal population, alternatives to incarceration, 620-621
- disasters and, long-term aftermath of, 403
- prescription opiates in,
 - contraindication to, 687
- psychiatric disorders in, screening for, 651
- relapse prevention in, pharmacologic, **627-648**
- self-medication hypothesis in, 290-291

Substantia nigra reticula, 759-760

Subthalamic nucleus (STN), 760

Sufentanil, addiction to, 745-747

Suicide, malpractice claims and, in addiction psychiatry, 616

- in Parkinson's disease, 802

Supportive techniques, post-disaster, 401

T

Tandospirone, for memory problems, in schizophrenia, 12

Tardive dyskinesia, neuroleptic-induced, 30

- risk factors for, in mood disorders, 30

Tauopathies, in Parkinson-related disorders, 798

Terror, psychology of, 402

Terrorism, from above vs. from below, 398-399

- debriefing and, future, 419
- definition of, 398
- media coverage of, 398
- mental health issues in, stage-specific approach to, 403
- psychological impact of, 399
- rumors related to biological or chemical weapons in, 401
- weapons of mass destruction and, 400-401
- psychological and physical manifestations of, 402

- Terrorism psychiatry, mass violence in,
early intervention in, for adverse
outcomes, 468-469
 best practice guidelines for,
 467
 components of, 468-469
 debriefing in, 469
 hierarchy of needs in,
 468
 planning of, 468
Pentagon attack on 9/11, family
assistance center for, 466
family casualty assistance care
officer, 466
group intervention activities,
465-466
responding agencies, 465
weapons of mass destruction and,
long-term reactions, 469
short-term reactions, 469
specific interventions in, 469-470
- Thalamus, in ADHD in children, 330
anatomy of, 59-60
in posttraumatic stress disorder,
attentional bias and, 61
dissociation and, 60-61
structure and function of, 330
- Therapeutic communities, for dual-
diagnosis patients, 714
interventions in, 716
- Tiagabine, for cocaine addiction, 641
- Tobacco use. *See Smoking.*
cardiovascular disease and,
675-677
and chronic respiratory disease, 677
lung cancer and, 675
nonrespiratory cancers and, 676
women's health and, 677
- Toddlers, posttraumatic stress in, 475
- Topiramate, for alcohol addiction, 636
for chronic PTSD, 443
- Tourette syndrome, obsessive-compulsive
disorder in, 40
- Trail Making Test, of visual search and
perceptual motor speed, in ADHD,
271-272
- Trauma psychiatry, disaster psychiatry vs.,
393
military issues in, 459-471. *See also*
War psychiatry.
- Traumatic amnesia, in posttraumatic stress
disorder, 56
thalamus and, in posttraumatic stress
disorder, 61-62
- Traumatic brain injury, obsessive-
compulsive disorder and, 40
- Traumatic stress disorder, in children,
characterization of, 485
intervention guidelines for, 486
with parents, 487
in preschoolers post-9/11, 473-489
- Trazodone, in children and adolescents,
116
- Tricyclic antidepressants (TCAs), for
ADHD, 373-374
for anhedonia in cocaine dependence,
654
in children and adolescents, 113-114
for major depressive episodes with
alcoholism, 653-654
-
- V**
- Vagus nerve stimulation, in pediatric
depressive disorders, 129-130
- Valproate sodium, for bipolar disorder, in
children and adolescents, 160-161
dosing of, 161
drug interactions with, 162
side effects of, 161-162
- Valproic acid, in chronic PTSD, 443
- Venlafaxine, for ADHD, 377
with alcohol and cocaine abuse,
292-293
with substance use disorder, 294
in pediatric depressive disorders, 124,
126
- Verbal memory, in obsessive-compulsive
disorder, 39
- Violence, political, effect on children, 473
-
- W**
- War psychiatry, current combat and
operational stress control efforts,
461-462
extension to mass trauma and
terrorism, 459-460
in Korean War, 460
prevention in, 462
training and discipline in, 462
unit bonding and morale,
462-463
for prisoners of war, 464-465
for return to duty, principles in,
proximity, immediacy,
expectancy, simplicity, 460
in World War II combat fatigue, 460
in World War I shell shock, 460

War psychiatry (*continued*)
for the wounded, 463-464

Wartime trauma, 408-411
military interventions in, 411

Weapons of mass destruction, rumors
related to, 401
threatened use of, as psychological
warfare, 400-401
use of, psychological and physical
manifestations of, 402

Wechsler Adult Intelligence Scale
(WAIS-R), subtests of, in ADHD,
272

Wender-Reimherr Adult Attention Deficit
Disorder Scales (WRAADS), 198

Wernicke-Korsakoff dementia, from
alcohol abuse, 100-102

Wisconsin Card Sorting Test (WCST), in
ADHD, in children vs. in adults,
272-273

Working memory, spatial, in depression, 26

X

X chromosome, DXS7 locus on,
in ADHD, 311

Z

Zaleplon, posttrauma, 439

Zolpidem, posttrauma, 439

